USFDA warning letter for Goa Plant 2 unresolved
The USFDA warning letter for Goa Plant 2 remains unresolved, limiting sterile product sales and requiring costly remediation and technology transfers.
INDOCO / Q3-FY26 / risks
Keep the risk register visible.
Indoco Remedies · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Elevated debt and repayment pressure
Consolidated debt of ~₹920 crore requires annual repayments of ₹135-140 crore, which may strain cash flows if growth disappoints.
Domestic acute therapy weakness persists
Domestic formulation revenue was flat due to unpredictable acute therapy demand, and management expressed uncertainty about near-term recovery.
Europe revenue growth delayed by customer approvals
European growth was pushed back by one quarter due to customer approval delays, and management noted that 90% of work is done but timing remains uncertain.